Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain and acute eye pain. Chromocell Therapeutics portfolio also includes several novel sublingual and intranasal single-use, disposable spray devices that are intended to treat various conditions including mild to moderate pain, acute migraine and nausea and vomiting associated with chemotherapy and surgery or anesthesia.